Inventiva is a clinical-stage biopharmaceutical company that focuses on developing novel oral small molecule therapies aimed at addressing significant unmet medical needs in various therapeutic areas, including fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary library of over 240,000 compounds and a dedicated research and development facility. Their scientific approach emphasizes the targeting of nuclear receptors, transcription factors, and epigenetic modulation, which are critical in the development of their drug candidates. Notably, Inventiva is advancing two clinical candidates, lanifibranor for non-alcoholic steatohepatitis (NASH) and odiparcil for mucopolysaccharidosis (MPS), both of which have shown promising results in clinical trials.

The panNASH initiative is a key component of Inventiva's research, focusing on the role of panPPAR agonism in treating NASH, a condition characterized by liver fat accumulation and inflammation. Lanifibranor has demonstrated significant efficacy in a phase IIb study, leading to its designation as a Breakthrough Therapy by the FDA. Similarly, odiparcil has shown a favorable safety profile and efficacy in adult MPS VI patients, particularly in tissues not adequately addressed by existing treatments. Through strategic partnerships and a commitment to innovative clinical programs, Inventiva aims to bring effective therapies to patients suffering from these challenging conditions.

France

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

Cancer

Liver Diseases

Lung Diseases

Inventiva

Fatty liver disease

Liver disease

Non-alcoholic steatohepatitis

Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and pre-clinical studies to date. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH.

Lanifibranor (Pan-PPAR)

Type 2 diabetes

Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and pre-clinical studies to date. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH.
Combination therapy with lanifibranor and empagliflozin (SGLT2 inhibitor) can provide additional benefits and further improve the cardiometabolic risk profile of patients with NASH.

Lanifibranor + empagliflozin

Genetic disorder

Mucopolysaccharidoses

Mucopolysaccharidosis type IV

Rare diseases

Rare genetic disease

<h3 class="font_3"> </h3>
Odiparcil is an orally-available small molecule that acts on the underlying cause of the symptoms of mucopolysaccharidosis (“MPS”), a group of rare, progressive genetic disorders. MPS is characterized by the accumulation of glycosaminoglycans (“GAGs”), polysaccharides which are important for the modulation of cell to cell signalling and the maintenance of tissue structure and function, in the lysosomes of cells. Due to genetic mutations, lysosomes in patients with MPS contain deficient versions of the enzymes necessary to break down GAGs. As a result, GAGs accumulate within the lysosomes, causing the latter to swell and interfere with the ordinary functioning of cells, leading to the symptoms associated with MPS. MPS is categorized by subtypes, depending on the enzyme that is deficient and the corresponding GAGs that accumulate. By modifying how GAGs are synthesized, odiparcil facilitates the production of soluble GAGs that can be excreted in the urine, rather than accumulating in cells. Specifically, odiparcil acts on chondroitin sulfate (“CS”) and dermatan sulfate (“DS”), either or both of which accumulate in patients with MPS I, II, IVa, VI and VII.

Odiparcil (GAG)

Carcinoma

Kidney cancer

Psoriasis

ABBV-157 is a small molecule inhibitor of RoRγT being investigated for the treatment of immune-mediated diseases (e.g. Psoriasis).

Cedirogant (ABBV-157) (60RORy)

Europe - West

Small Molecule Pharmaceuticals

Therapeutic

Inventiva

Company Details